| Disease |
| Disease |
Method |
Sample |
Expression pattern |
Dysfunction type |
Description |
PMID |
Source |
| colorectal cancer |
limiting dilution and serial tumor formation assay |
colorectal cancer stem cells |
N/A |
interaction |
Large intergenic non-coding RNA p21 (lincRNA-p21) is a potent suppressor of stem-like traits of CSCs purified from both primary colorectal cancer (CRC) tissues and cell lines. Ad-lnc-p21-MRE significantly suppressed the self-renewal potential and tumorigenicity of CSCs in nude mice. |
26497997 |
|
| lung cancer |
N/A |
N/A |
N/A |
expression |
lincRNAp21 is required for the global repression of genes that interfere with p53 function regulating cellular apoptosis. lincRNAp21 can mediate gene repression by physically interacting with the protein hnRNP-K, allowing its localization to promoters of genes to be repressed in a p53-dependent manner, and its overexpression in a lung cancer cell line sensitizes the cells to DNA |
22535282 |
LncRNADisease
|
| atherosclerosis |
N/A |
N/A |
N/A |
N/A |
The expression of lincRNA-p21 was dramatically downregulated in atherosclerotic plaques of ApoE(-/-) mice, an animal model for atherosclerosis. LincRNA-p21 represses cell proliferation and induces apoptosis in vascular smooth muscle cells and mouse mononuclear macrophage cells in vitro |
25156994 |
LncRNADisease
|
| lung cancer |
qPCR etc. |
cell lines (wt MEFs, NIH/3T3 MEFs etc.) |
down-regulated |
expression |
Gas5 has also been linked with breast cancer because Gas5 transcript levels are significantly reduced compared to unaffected normal breast epithelia. |
20673990 |
LncRNADisease Lnc2Cancer
|
| cervical cancer |
qPCR etc. |
cell line (CaSki) |
up-regulated |
N/A |
Generally, we found that some of the RNA molecules (HOTAIR and MALAT1) are down-regulated while many of them (lincRNA-p21, GAS5, MEG3, ANRIL, and ncRNA-CCND1) are up-regulated and some others (TUG1, UCA1, and PANDA) not affected. The decline in the expression of HOTAIR and MALAT1 was clearly evident in BLM-treated HeLa and MCF cells. For lincRNA-p21, ncRNA-CCND1, and MEG3, a similar up-regulation pattern was obvious in both cell lines where the increase was generally more pronounced in BLM-treated cells. |
22487937 |
LncRNADisease Lnc2Cancer
|
| chronic lymphocytic leukemia |
qPCR etc. |
blood (plasma) |
down-regulated |
expression |
HOTAIR long non-coding RNA is a negative prognostic factor not only in primary tumors, but also in the blood of colorectal cancer patients. |
24583225 |
LncRNADisease Lnc2Cancer
|
| prostate cancer |
qPCR etc. |
prostate cancer tissue |
up-regulated |
expression |
The lincRNA-p21 levels were significantly higher in PCa than in BPH. Our data suggest that the discriminative potential of exosomal lincRNA-p21 levels may help to improve the diagnostic prediction of the malignant state for patients with PCa. |
25999983 |
Lnc2Cancer
|
| B cell lymphoma |
qPCR, Western blot etc. |
B cell lymphoma tissue, DLBCL cell lines (SU-DHL-2, OCI-LY-3, OCILY-10, SU-DHL-4, OCI-LY-7) |
down-regulated |
interaction |
We found that lincRNA-p21 levels were markedly decreased in DLBCL tissues compared with normal. Its expression level was significantly correlated with Ann Arbor stages, B symptoms, performance status, IPI score and serum LDH. Moreover, patients with high levels of LincRNA-p21 expression had a favorable overall survival and progression-free survival. Furthermore, ectopic expression of lincRNA-p21 inhibited cell proliferation, arrested cycle progression and modulated cyclin D1, CDK4 and p21 expression in DLBCL cell lines. These results demonstrated lincRNA-p21 can be identified as a potential novel prognostic biomarker for prognosis in DLBCL and regulate cell proliferation and cycle in vitro |
26475621 |
Lnc2Cancer
|
| colorectal cancer |
qPCR, Western blot, knockdown etc. |
CRC tissue, cell lines (SW1116, SW620, LS 174T, HT29, LOVO etc.) |
down-regulated |
regulation |
LincRNA-p21 enhances the sensitivity of radiotherapy for human colorectal cancer by targeting the Wnt/β-catenin signaling pathway. |
24573322 |
LncRNADisease Lnc2Cancer
|
| Burkitt's lymphoma |
qPCR, Western blot, knockdown etc. |
blood |
up-regulated |
expression |
We analyzed its expression in CLL and lymphoma in the context of DNA damage. 24 hours after IR, lincRNA-p21 expression was strongly induced in a p53-dependent manner in a very large set of CLL patients (n = 73).lncRNAs NEAT1 and lincRNA-p21 as novel elements of the p53-dependent DNA damage response machinery in CLL and lymphoma. |
25971364 |
Lnc2Cancer
|
| chronic lymphocytic leukemia |
qPCR, Western blot, knockdown etc. |
blood |
up-regulated |
expression |
We analyzed its expression in CLL and lymphoma in the context of DNA damage. 24 hours after IR, lincRNA-p21 expression was strongly induced in a p53-dependent manner in a very large set of CLL patients (n = 73).lncRNAs NEAT1 and lincRNA-p21 as novel elements of the p53-dependent DNA damage response machinery in CLL and lymphoma. |
25971364 |
Lnc2Cancer
|
| hepatocelluar carcinoma |
qPCR, Western blot, knockdown etc. |
hepatocellular cancer tissue |
down-regulated |
expression |
We demonstrated that lincRNA-p21 acted as a tumor suppressive lncRNA in human hepatocellular carcinoma. We firstly found the downregulation of lincRNA-p21 level in human hepatocellular carcinoma tissues, and showed that low expression of lincRNA-p21 was associated with high disease stage and predicted poor survival.We showed that lincRNA-p21 knockdown promoted proliferation and colony formation of HepG2, Huh7 and Bel-7042 cells in vitro, while lincRNA-p21 overexpression obtained oppose results.We demonstrated that ER stress accounted for lincRNA-p21 effects on apoptosis, proliferation and in vivo growth of hepatocellular carcinoma. |
26305675 |
Lnc2Cancer
|
| |